Skip to content
Vabysmo(faricimab)
Vabysmo (faricimab) is an antibody pharmaceutical. Faricimab was first approved as Vabysmo on 2022-01-28. It is used to treat diabetic retinopathy in the USA. It has been approved in Europe to treat diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A and angiopoietin-2. In addition, it is known to target Vascular endothelial growth factor A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Vabysmo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Faricimab
Tradename
Proper name
Company
Number
Date
Products
Vabysmofaricimab-svoaGenentechN-761235 RX2022-01-28
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
vabysmoBiologic Licensing Application2022-02-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic retinopathyEFO_0003770D003930—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular edemaD008269—263112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30112—15
Retinal vein occlusionD012170EFO_1001157H34.81——2——2
Wet macular degenerationD057135EFO_0004683——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Choroidal neovascularizationD020256—2———2
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFARICIMAB
INNfaricimab
Description
Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4297750
ChEBI ID—
PubChem CID—
DrugBankDB15303
UNII IDQC4F7FKK7I (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
ANGPT2
ANGPT2
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
7422
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
P15692
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
H0YBI8
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Vabysmo - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 295 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13 adverse events reported
View more details